https://www.selleckchem.com/products/z-ietd-fmk.html Laminarin supplementation reduced FS compared with unsupplemented pigs but had no major effect on the microbiota compared with the unsupplemented pigs. There were CP concentration × additive interactions on both Firmicutes and Proteobacteria. Firmicutes were increased in the LCP ZnO group compared with the LCP group, but there was no difference between the SCP groups. Proteobacteria were reduced in the LCP ZnO group compared with the LCP and LCP LAM groups (p less then .05), but there was no difference between the SCP groups. In conclusion, reducing CP did not improve FS; it increased the relative abundance of Enterobacteriaceae; however, it also increased bacterial diversity. Supplementation with ZnO and laminarin improved FS, although all groups had scores within the healthy range. ZnO altered the large intestinal microbiota and VFA concentrations; however, laminarin did not enhance these parameters, suggesting these compounds have differing modes of action. Many researchers argue that Alzheimer's disease is at least partly caused by deposition of amyloid beta (Aβ) in the brain. Ferulic acid (FA) and Angelica archangelica (AA) are candidate agents for reducing Aβ and improving cognitive function. Feru-guard 100M is a supplement containing FA and AA extract. Using this supplement, we planned to assess the effect of FA and AA on Aβ deposition in the human brain. This was an open-label, interventional multi-institutional joint study of Kobe University and the Institute of Biomedical Research and Innovation (Kobe, Japan). Seventeen subjects diagnosed with mild cognitive impairment were divided into two groups the intervention group (n = 10) and the control group (n = 7). The subjects in the intervention group used Feru-guard 100M every day for 48 weeks, whereas the subjects in the control group did not use the supplement. We assessed the differences between the two groups by examining Aβ deposition and brain atrophy